Gilead Sciences, Inc. (GILD)
| Market Cap | 115.17B |
| Revenue (ttm) | 28.30B |
| Net Income (ttm) | 126.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.10 |
| PE Ratio | 951.61 |
| Forward PE | 12.60 |
| Dividend | $3.08 (3.33%) |
| Ex-Dividend Date | Dec 13, 2024 |
| Volume | 5,523,787 |
| Open | 91.44 |
| Previous Close | 91.35 |
| Day's Range | 91.44 - 92.90 |
| 52-Week Range | 62.07 - 98.90 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 95.32 (+3.15%) |
| Earnings Date | Nov 6, 2024 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $95.32, which is an increase of 3.15% from the latest price.
News
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company's pivotal Phase 3 PURP...
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.
BETHESDA, Md.--(BUSINESS WIRE)--The Children's Inn at the National Institutes of Health (NIH) today announced that Gilead Sciences Inc. has awarded The Inn a $1 million grant to support its renovation...
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ET Company Participants Dan O'Day - Chairman and CEO Andy Dickinson - CFO Conference Call Par...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%...
Gilead Sciences to close Seattle office; shutdown impacts 72 employees
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday.
Gilead Prices $3.5 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today annou...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stud...
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a b...
Gilead Sciences: Finally Some Real Momentum
Shares of Gilead Sciences, Inc. experienced a downturn early in 2024 due to pipeline setbacks and underwhelming guidance, but shares have seen a significant recovery recently. The company's reliance o...
Gilead Sciences to Present at Upcoming Investor Engagements
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthca...
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead Sciences Inc GILD stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its fiscal year 2024 guidance.
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio and increased demand for COVID-19 therapy Veklury. Oncology remains a weak area, with CAR-T ...
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infec...
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance
Gilead Sciences Inc.'s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 ...
Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for full-year earnings.
Gilead Sciences Announces Third Quarter 2024 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead's third quarter results are the strongest o...
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfo...
Top 2 pharma stocks to buy amid surge in deadly fungi
Recent data cited by Bloomberg reveals that deadly fungi, including Candida auris, have been spreading globally since the COVID-19 pandemic. Climate change has enabled many of these illness-causing ag...
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the American Association for the Study of ...
Calls of the Day: Gilead, Berkshire Hathaway and SLB
The Investment Committee debate the latest Calls Of The Day
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from...